Asset Details
Do you wish to reserve the book?
Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in Crohn’s disease: a retrospective single-center study with translational analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in Crohn’s disease: a retrospective single-center study with translational analysis
Do you wish to request the book?
Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in Crohn’s disease: a retrospective single-center study with translational analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in Crohn’s disease: a retrospective single-center study with translational analysis
2025
Overview
Background and aim
Few studies have evaluated the impact of biologic therapy on endoscopic findings and stenoses of small intestinal lesions in Crohn’s disease (CD). This study aimed to compare the endoscopic effectiveness and stenotic changes induced by anti-tumor necrosis factor inhibitors (anti-TNF) and ustekinumab (UST) in patients with CD, along with histological and molecular comparisons of stenosis between the groups.
Methods
We retrospectively enrolled patients with CD who underwent balloon-assisted enteroscopy before and after initiating anti-TNF therapy or UST. For pathological and molecular evaluation of stenosis, we analyzed resected ileal specimens from patients with CD treated with anti-TNF, UST, or those who were biologic-naïve (bio-naïve).
Results
The anti-TNF group (
n
= 18) showed a higher improvement rate in endoscopic activity scores compared to the UST group (
n
= 19). However, 27.8% of patients in the anti-TNF group experienced worsened stenosis, significantly higher than that in the UST group (0%). Histologically, the UST group showed a lower fibrosis score and reduced collagen III protein expression in the inactive ileum compared to both the anti-TNF and bio-naïve groups. Additionally, the UST group exhibited lower mRNA levels of
IL22
,
TGFB1
, and
TNF
in both active and inactive ilea. Immunostaining revealed fewer α-smooth muscle actin-positive cells in the UST group compared to the anti-TNF and bio-naïve groups in both active and inactive ileum.
Conclusion
This study suggests that inhibition of the IL-22/TGF-β pathway by anti-IL-23 treatment with UST may reduce myofibroblasts and improve small intestinal fibrous stenosis in patients with CD.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Adult
/ Analysis
/ Collagen
/ Collagen Type III - metabolism
/ Constriction, Pathologic - drug therapy
/ Constriction, Pathologic - etiology
/ Constriction, Pathologic - pathology
/ Crohn Disease - complications
/ Crohn Disease - drug therapy
/ Female
/ Fibrosis
/ Humans
/ Intestinal Obstruction - drug therapy
/ Intestinal Obstruction - etiology
/ Intestinal Obstruction - pathology
/ Male
/ Medicine
/ RNA
/ Stenosis
/ Transforming Growth Factor beta1 - genetics
/ Transforming Growth Factor beta1 - metabolism
/ Tumor Necrosis Factor Inhibitors - therapeutic use
/ Tumor Necrosis Factor-alpha - antagonists & inhibitors
